Brukinsa (zanubrutinib) Approved in the U.S. for Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), manufactured by the biotechnology company BeiGene, which is a next-generation BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
The FDA reported that the most common adverse reactions seen with zanubrutinib were a decrease in neutrophil count, upper respiratory tract infection, decrease in platelet count, hemorrhage, and musculoskeletal pain.
